We are live on ! Find out more
Longaeva Partners

Longaeva Partners Portfolio holdings

AUM $4.58B Turnover 75.17%
1-Year Est. Return 43.91%
This Fund
S&P 500
This Quarter Est. Return
+20.82%
1 Year Est. Return
+43.91%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.58B
AUM Growth
+$1.88B
Cap. Flow
+$1.03B
Cap. Flow %
22.6%
Top 10 Hldgs %
29.9%
Holding
435
New
231
Increased
47
Reduced
58
Closed
96
Avg Time Held Equity + Options
0.1 years
Top 10 Avg Time Held Equity + Options
0 years
Top 20 Avg Time Held Equity + Options
0.1 years
Avg Time Held Equity only
0.1 years
Top 10 Avg Time Held Equity only
0.1 years
Top 20 Avg Time Held Equity only
0.1 years

Top Buys

Rank Stock Value
1
SPCX icon
SpaceX
SPCX
+$101M
2
JPM icon
JPMorgan Chase
JPM
+$79.2M
3
MCO icon
Moody's
MCO
+$58.8M
4
FITB icon
Fifth Third Bancorp
FITB
+$58.5M
5
LPLA icon
LPL Financial
LPLA
+$56M

Sector Composition

Rank Sector Weight
1 Miscellaneous 24.82%
2 Financials 20.39%
3 Healthcare 17.29%
4 Industrials 14.57%
5 Technology 7.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
LUV icon
376
Southwest Airlines
LUV
$21.8B
– –
-154,535
Closed -$5.81M –
MA icon
377
Mastercard
MA
$571B
– –
-85,782
Closed -$42.9M –
META icon
378
Meta Platforms (Facebook)
META
$1.55T
– –
-29,436
Closed -$18M –
MRAM icon
379
Everspin Technologies
MRAM
$262M
– –
-172,774
Closed -$1.52M –
MSCI icon
380
MSCI
MSCI
$47.7B
– –
-77,680
Closed -$41.9M –
MTB icon
381
M&T Bank
MTB
$31.6B
– –
-5,261
Closed -$1.09M –
NOC icon
382
Northrop Grumman
NOC
$74.6B
– –
-6,271
Closed -$4.28M –
NRIX icon
383
Nurix Therapeutics
NRIX
$1.62B
– –
-1,490,202
Closed -$23.1M –
NVDA icon
384
CALL
NVIDIA
NVDA
$4.39T
– –
-329,000
Closed -$57.4M –
ONB icon
385
Old National Bancorp
ONB
$9.48B
– –
-464,469
Closed -$10.3M –
PAYX icon
386
Paychex
PAYX
$42.5B
– –
-4,601
Closed -$424K –
PFE icon
387
Pfizer
PFE
$170B
– –
-560,615
Closed -$14.7M –
PIPR icon
388
Piper Sandler
PIPR
$4.74B
– –
-211,601
Closed -$16.2M –
PJT icon
389
PJT Partners
PJT
$3.92B
– –
-154,987
Closed -$21.7M –
PLXS icon
390
Plexus
PLXS
$5B
– –
-14,334
Closed -$2.9M –
PMVP icon
391
PMV Pharmaceuticals
PMVP
$67.9M
– –
-552,027
Closed -$685K –
PNC icon
392
PNC Financial Services
PNC
$90.5B
– –
-326,695
Closed -$68M –
PTON icon
393
Peloton Interactive
PTON
$2.48B
– –
-77,110
Closed -$331K –
QQQ icon
394
Invesco QQQ Trust
QQQ
$437B
– –
-246
Closed -$169K –
RH icon
395
RH
RH
$2.6B
– –
-1,497
Closed -$209K –
RLAY icon
396
Relay Therapeutics
RLAY
$3.73B
– –
-470,544
Closed -$4.68M –
ROKU icon
397
Roku
ROKU
$23.8B
– –
-14,608
Closed -$1.38M –
SCHW icon
398
Charles Schwab
SCHW
$160B
– –
-349,153
Closed -$32.8M –
SHAK icon
399
Shake Shack
SHAK
$2.82B
– –
-39,530
Closed -$3.5M –
SMMT icon
400
Summit Therapeutics
SMMT
$11.3B
– –
-57,282
Closed -$1.09M –

Similar funds

Longaeva Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Longaeva Partners held 435 positions worth $4.58B, up 69% from $2.7B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Longaeva Partners deployed $1.03B of net new capital in Q2 2026, opening 231 new positions and adding to 47 existing holdings. Its largest new stake was SpaceX: 596,829 shares worth $102M.

By sector, the portfolio is most concentrated in Miscellaneous at 25% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.

On the sell side, the largest reduction was ACM Research, an estimated $48.8M trimmed.

  • Longaeva Partners's largest Q2 2026 buy was SpaceX: 596,829 shares worth $102M.
  • Longaeva Partners added most to Mettler-Toledo International in Q2 2026, an estimated $39.4M increase.
  • Longaeva Partners's biggest Q2 2026 reduction was ACM Research, cutting an estimated $48.8M.
  • Longaeva Partners fully exited PNC Financial Services in Q2 2026, selling an estimated $68M.
  • Longaeva Partners's ten largest holdings make up 30% of its $4.58B portfolio in Q2 2026.
  • Longaeva Partners opened 231 new positions and closed 96 in Q2 2026.
  • Longaeva Partners's portfolio value rose 69% quarter-over-quarter to $4.58B.

Based on Longaeva Partners's 13F filing for Q2 2026, filed 14 Aug 2026.